Big Pharma’s 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders

Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference arsenic ample drugmakers look looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing astir strategical capital: radiopharmaceuticals, next-gen GLP-1, autologous CAR-T, allogeneic compartment therapy, and antibody-drug conjugates. Below are the publically traded class leaders successful each. Each is simply a well-positioned standalone concern with M&A optionality, not a takeout prediction.

5. ADC Therapeutics: Pure-Play ADCs

ADC Therapeutics (NYSE: ADCT) is 1 of the fewer remaining pure-play, commercial-stage ADC names aft Pfizer paid $43 cardinal for Seagen and AbbVie bought ImmunoGen. Lead cause Zynlonta generated $20.03 cardinal successful Q1 2026 nett merchandise revenue, up 15% twelvemonth implicit year, and Q1 gross of $20.85 cardinal bushed the statement estimate.

The large catalyst is LOTIS-5 Phase 3 topline information expected successful Q2 2026, with highest U.S. gross imaginable pegged astatine $600 cardinal to $1 cardinal and currency runway into 2028. Risks see antagonistic shareholders' equity of $216.4 million, a Portnoy Law Firm probe announced successful April 2026 implicit LOTIS-7 safety, and Redmile Group disposing astir 5.9 cardinal shares successful aboriginal April 2026. Shares commercialized adjacent $3.50 apiece.

The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and ADC Therapeutics wasn't 1 of them. Get them present FREE.

4. Allogene Therapeutics: Off-the-Shelf CAR-T

Allogene Therapeutics (NASDAQ: ALLO) leads the allogeneic CAR-T class that large pharma views arsenic the manufacturing solution to the scalability challenges of patient-specific autologous therapy. The ALPHA3 interim investigation showed 58.3% measurable residual illness (MRD) clearance, versus 16.7% successful the reflection arm, with nary cytokine merchandise syndrome, immune effector cell-associated neurotoxicity syndrome, oregon graft-versus-host disease. Q1 EPS met expectations astatine −$0.18, and an April 2026 rise of $200.4 cardinal (gross) extended the runway into Q1 2029.

The situation is scale. The marketplace headdress is astir $803.9 million, the banal trades adjacent $2.30, and shares are down 23.9% implicit the past period aft the dilutive offering. Long-dated catalysts (interim EFS mid-2027) support this successful the higher-risk bucket.